A comparative study on the immunogenicity, safety and tolerance of purified duck embryo vaccine (PDEV) manufactured in India (Vaxirab) and Switzerland (Lyssavac-N): A randomized simulated post-exposure study in healthy volunteers

Vaccine

Volumn 25, Issue 50, 2007, Pages 8405-8409

  Mahendra, Bangalore Jayakrishnappa ^a   Madhusudana, Shampur Narayan ^b   Ashwathnarayana, Doddabele Hanumanthaiah ^a   Sampath, Gadey ^c   datta, Soma Subhra ^d   Sudarshan, Mysore Kalappa ^a   Venkatesh, Gonibeedu Manjunatah ^a   Muhamuda, Kader ^b   Bilagumba, Gangaboraiah ^a   Shamanna, Manjula ^e  

^a KEMPEGOWDA INSTITUTE OF MEDICAL SCIENCES   (India)

^b NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

^c Institute of Preventive Medicine   (India)

^d Pasteur Institute   (India)

^e ZYDUS RESEARCH CENTRE   (India)

Author keywords

Purified duck embryo vaccine; Rabies; Rabies prophylaxis; Rabies vaccines

Indexed keywords

RABIES VACCINE; UNCLASSIFIED DRUG; VAXIRAB;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; MALE; MULTICENTER STUDY; MYALGIA; NORMAL HUMAN; PAIN; PRIORITY JOURNAL; PRURITUS; RABIES; RANDOMIZED CONTROLLED TRIAL; SKIN INDURATION; UNSPECIFIED SIDE EFFECT; URTICARIA; WEAKNESS;

ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, VIRAL; CELL LINE; CHEMOPREVENTION; CRICETINAE; DUCKS; FEMALE; HUMANS; INDIA; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; RABIES; RABIES VACCINES; RABIES VIRUS; SWITZERLAND;

EID: 36348938295     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.10.002     Document Type: Article

References (16)

1. World Health Organization. World survey of rabies no. 35 for the year 1999. WHO/CDS/CSR/EPH/2002.10. Geneva.
2. Sudarshan M.K., Madhusudana S.N., Mahendra B.J., et al. Assessing burden of human rabies in India: results of a national multi-center epidemiological survey. Int J Infect Dis 11 1 (2007) 29-35
3. Krebs J.W., Mandel E.J., Swerdlon P.L., and Rupprecht C.E. Rabies surveillance in the USA during 2004. J Am Vet Assoc 227 12 (2005) 1912-1925
4. World Health Organization. WHO expert consultation on rabies. First report. WHO Tech Rep Ser 931. Geneva: WHO; 2005.
5. Gluck R., Matthieu J.M., Wegman A., and Mean F. Absence of myelin basic protein in an improved purified duck embryo vaccine. Neurochem Pathol 4 2 (1986) 69-75
6. Wegmann A., Gluck R., Keller H., and Matthieu J.M. A highly efficient, highly purified duck embryo rabies vaccine. Schweiz Med Wochenchr 115 (1985) 1779G-1781G
7. Kamoltham T., Singhsa J., Promsaranee U., Sonthon P., Mathean P., and Thinyounyong W. Elimination of human rabies in a canine endemic province in Thailand: five year programme. Bull World Health Organ 81 5 (2003) 375-381
8. Wild H., Tipkong P., and Khawplod P. Economic issues in post exposure rabies treatment. J Travel Med 6 4 (1999) 238-242
9. Gluck R. Purified duck embryo vaccine for humans. In: Meslin F.X., Kaplan M.M., and Koprowsky H. (Eds). Laboratory techniques in rabies. 4th ed. (1996), WHO, Geneva 253-269
10. Khawplod P., Gluck R., Wild H., et al. Immunogenicity of purified duck embryo vaccine (Lyssavac-N) with use of the WHO-approved intradermal post-exposure regimen. Clin Infect Dis 20 3 (1995) 646-651
11. World Health Organization. WHO expert committee on rabies. 8th Report. WHO Tech Rep Ser 824. Geneva: WHO; 1992.
12. Smith J.S., Yager P.A., and Baer G.M. A rapid fluorescent focus inhibition test (RFFIT) for determining rabies-neutralizing antibody. In: Meslin F.X., Koprowsky H., and Kaplan M.M. (Eds). Laboratory techniques in rabies. 4th ed. (1996), WHO, Geneva 181-192
13. Sudarshan M.K., Mahendra B.J., Madhusudana S.N., et al. Assessing the relationship between antigenicity and immunogenicity of human rabies vaccines: results of a meta-analysis. Hum Vaccine 1 5 (2005) 187-190
14. Beran J., Honegr K., Banzhof A., and Malerczyk C. Potency requirements of rabies vaccines administered intradermally using the Thai Red Cross regimen: investigation of the immunogenicity of serially diluted purified chick embryo Cell rabies vaccine. Vaccine 23 30 (2005) 3902-3907
15. Nicholson K.G. Cell culture vaccines for human use: general considerations. In: Meslin F.X., Koprowsky H., and Kaplan M.M. (Eds). Laboratory techniques in rabies. 4th ed. (1996), WHO, Geneva 271-279
16. Gluck R., Wegmann A., Germanier R., Keller H., Hess M.W., Kraus-Ruppert R., et al. A new highly immunogenic duck embryo rabies vaccine. Lancet I (1984) 844-845